Related Experiment Video
Updated: Aug 5, 2026

Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Transcriptomic Study of Diffuse Large B-Cell Lymphoma Associated with HIV Infection: Identification of Novel
Yasmine Labiad1, Céline Baier1, Michèle Genin2
1Aix Marseille Univ, TAGC/INSERM UMR1090, Parc Scientifique de Luminy, Marseille, France.
Abstract:
Objectives: Transcriptomic profiling has enabled the classification of Diffuse Large B-Cell Lymphoma (DLBCL) into distinct subtypes, such as Germinal Center B-cell-like (GCB) and Activated B-cell-like (ABC), primarily in HIV-negative patients. However, HIV-associated DLBCL may follow different molecular mechanisms due to immune dysregulation. This study aimed to characterize the transcriptomic landscape of HIV-related DLBCL to identify distinct subtypes and deregulated pathways with potential theranostic implications. Methods: Twelve formalin-fixed, paraffin-embedded DLBCL samples from HIV-positive patients were analyzed using Agilent's microarray. Quantile normalization and unsupervised hierarchical clustering were performed to classify tumors based on gene expression profiles. Results: Two distinct transcriptomic subgroups were identified. TP53 and BCL7A were overexpressed in cluster I, while BCL2 was overexpressed in cluster II. Notably, the "immune system development" pathway was under expressed in cluster I compared to cluster II. Conclusions: Our findings reveal two molecularly distinct subtypes of HIV-associated DLBCL, likely driven by differences in tumor microenvironment and immune status. These transcriptomic profiles may guide future targeted therapies. Further validation in larger cohorts and integration with proteomic and clinical data are warranted to develop a comprehensive theranostic framework.
